DE602006000102T2 - Indanyl-piperazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen - Google Patents

Indanyl-piperazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen Download PDF

Info

Publication number
DE602006000102T2
DE602006000102T2 DE602006000102T DE602006000102T DE602006000102T2 DE 602006000102 T2 DE602006000102 T2 DE 602006000102T2 DE 602006000102 T DE602006000102 T DE 602006000102T DE 602006000102 T DE602006000102 T DE 602006000102T DE 602006000102 T2 DE602006000102 T2 DE 602006000102T2
Authority
DE
Germany
Prior art keywords
compound
piperazinyl
formula
indanecarboxamide
expected product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006000102T
Other languages
German (de)
English (en)
Other versions
DE602006000102D1 (de
Inventor
Guillaume De Nanteuil
Bernard Portevin
Philippe Gloanec
Mark Millan
Jean-Claude Ortuno
Clotilde Mannoury La Cour
Alain Gobert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of DE602006000102D1 publication Critical patent/DE602006000102D1/de
Application granted granted Critical
Publication of DE602006000102T2 publication Critical patent/DE602006000102T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
DE602006000102T 2005-03-30 2006-03-29 Indanyl-piperazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen Active DE602006000102T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503071A FR2883876B1 (fr) 2005-03-30 2005-03-30 Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR0503071 2005-03-30

Publications (2)

Publication Number Publication Date
DE602006000102D1 DE602006000102D1 (de) 2007-10-25
DE602006000102T2 true DE602006000102T2 (de) 2008-06-26

Family

ID=35079249

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006000102T Active DE602006000102T2 (de) 2005-03-30 2006-03-29 Indanyl-piperazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen

Country Status (37)

Country Link
US (1) US7442692B2 (ru)
EP (1) EP1707564B1 (ru)
JP (1) JP4503549B2 (ru)
KR (1) KR100766664B1 (ru)
CN (1) CN100467458C (ru)
AP (1) AP2007004169A0 (ru)
AR (1) AR054747A1 (ru)
AT (1) ATE372992T1 (ru)
AU (1) AU2006201326A1 (ru)
BR (1) BRPI0602132A (ru)
CA (1) CA2541066C (ru)
CR (1) CR9391A (ru)
CY (1) CY1107028T1 (ru)
DE (1) DE602006000102T2 (ru)
DK (1) DK1707564T3 (ru)
EA (1) EA010051B1 (ru)
ES (1) ES2293630T3 (ru)
FR (1) FR2883876B1 (ru)
GE (1) GEP20084544B (ru)
GT (1) GT200700084A (ru)
HK (1) HK1096386A1 (ru)
HR (1) HRP20070498T3 (ru)
IL (1) IL186062A (ru)
MA (1) MA28211A1 (ru)
MX (1) MXPA06003552A (ru)
MY (1) MY140325A (ru)
NO (1) NO20061334L (ru)
NZ (1) NZ546186A (ru)
PL (1) PL1707564T3 (ru)
PT (1) PT1707564E (ru)
RS (1) RS50527B (ru)
SG (1) SG126113A1 (ru)
SI (1) SI1707564T1 (ru)
TN (1) TNSN07357A1 (ru)
UA (1) UA87989C2 (ru)
WO (1) WO2006103342A2 (ru)
ZA (1) ZA200602631B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071778B2 (en) * 2006-07-27 2011-12-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
US20090018163A1 (en) * 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
US7632861B2 (en) * 2007-11-13 2009-12-15 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
EP3628672A1 (en) 2018-09-25 2020-04-01 Antabio SAS Indane derivatives for use in the treatment of bacterial infection
WO2020064175A1 (en) 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
MA53707A (fr) 2018-09-25 2021-12-29 Antabio Sas Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
EP3628666A1 (en) 2018-09-25 2020-04-01 Antabio SAS Indane derivatives for use in the treatment of bacterial infection
EP4125883A1 (en) 2020-03-24 2023-02-08 Antabio SAS Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DK286990D0 (da) * 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
CA2175395A1 (en) * 1995-06-02 1996-12-03 Ronald J. Mattson Melatonergic indanyl piperazines or homopiperazines
FR2769312B1 (fr) * 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2827284B1 (fr) * 2001-07-16 2003-10-31 Servier Lab Nouveaux derives de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2503844A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity

Also Published As

Publication number Publication date
NZ546186A (en) 2007-04-27
MY140325A (en) 2009-12-31
RS50527B (sr) 2010-05-07
WO2006103342A2 (fr) 2006-10-05
HRP20070498T3 (en) 2007-12-31
NO20061334L (no) 2006-10-02
US20060223830A1 (en) 2006-10-05
AP2007004169A0 (en) 2007-10-31
AR054747A1 (es) 2007-07-11
EP1707564A3 (fr) 2006-11-15
AU2006201326A1 (en) 2006-10-19
CR9391A (es) 2008-01-21
SG126113A1 (en) 2006-10-30
CA2541066A1 (fr) 2006-09-30
ES2293630T3 (es) 2008-03-16
SI1707564T1 (sl) 2007-12-31
GT200700084A (es) 2009-05-22
IL186062A (en) 2010-12-30
IL186062A0 (en) 2008-01-20
ATE372992T1 (de) 2007-09-15
HK1096386A1 (en) 2007-06-01
ZA200602631B (en) 2007-06-27
EA200600487A1 (ru) 2006-10-27
GEP20084544B (en) 2008-11-25
KR100766664B1 (ko) 2007-10-12
KR20060105606A (ko) 2006-10-11
CA2541066C (fr) 2010-08-24
EA010051B1 (ru) 2008-06-30
WO2006103342A8 (fr) 2007-12-21
MXPA06003552A (es) 2006-09-29
WO2006103342A3 (fr) 2006-12-07
US7442692B2 (en) 2008-10-28
DE602006000102D1 (de) 2007-10-25
CY1107028T1 (el) 2012-09-26
PT1707564E (pt) 2007-10-16
JP4503549B2 (ja) 2010-07-14
JP2006282669A (ja) 2006-10-19
FR2883876B1 (fr) 2007-05-04
MA28211A1 (fr) 2006-10-02
EP1707564B1 (fr) 2007-09-12
TNSN07357A1 (en) 2008-12-31
CN100467458C (zh) 2009-03-11
UA87989C2 (ru) 2009-09-10
DK1707564T3 (da) 2008-01-21
EP1707564A2 (fr) 2006-10-04
BRPI0602132A (pt) 2007-08-14
WO2006103342A9 (fr) 2007-10-25
CN1840527A (zh) 2006-10-04
PL1707564T3 (pl) 2008-01-31
FR2883876A1 (fr) 2006-10-06

Similar Documents

Publication Publication Date Title
DE602006000102T2 (de) Indanyl-piperazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69905738T2 (de) Amidinderivate, ihre herstellung, ihre verwendung in medikamenten und sie enthaltende pharmazeutische zubereitungen
DE60312998T2 (de) 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
AT390951B (de) Verfahren zur herstellung von neuen 1-fluorphenylbutyl-4-(2-pyrimidinyl)-piperazinderivaten
DE60222248T2 (de) Aminomethylgruppen enthaltende n-(arylsulfonyl)beta-aminosäure-derivate, verfahren zu deren herstellung sowie deren pharmazeutische zubereitungen
DE602005005456T2 (de) Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen
DE2954639C2 (ru)
DE60104776T2 (de) Diphenylharnstoffderivate und deren Verwendung als alpha2/5-HT2c Antagonisten
DE3433327A1 (de) 1-heteroaryl-4-((2,5-pyrrolidindion-1-yl)alkyl)piperazinderivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
DE3248138C2 (ru)
EP1611107B1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
DE69819903T2 (de) Bicyclische verbindungen als liganden der 5-ht1 rezeptoren
DD149071A5 (de) Herstellung 2-substituierter trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole
WO2001014342A1 (de) Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DD287496A5 (de) Verfahren zur herstellung von 4-phenyl-3-butensaeurederivaten
ES2286474T3 (es) Derivados de 4-(finilpiperazinilmetil) benzamida y su uso para el tratamiento de dolor o transtornos gastrointestinales.
DE3442860A1 (de) 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3- on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE602006000283T2 (de) Piperazinderivate und ihre Verwendung als Serotonin-Wiederaufnahme-Inhibitoren oder als Neurokinin-Antagonisten
DE3900028A1 (de) Gegebenenfalls am phenylrest halogen- und/oder alkyl- und/oder alkoxy- oder methylendioxysubstituierte, 5,5-di-(methyl)-3-(phenylvinyl)-1-(substituiert amino-alkoxy-imino)-cyclohex-2-enderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
CH635834A5 (de) Dibenzo(d,g)(1,3,6)dioxazocin-derivate, verfahren zu ihrer herstellung und die diese verbindungen enthaltenden arzneimittelpraeparate.
DE3331612A1 (de) Substituierte 1-pyridyloxy-3-indolylalkylamino-2-propanole, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
EP1220845B1 (de) Arylsulfonamid-substituierte benzimidazolderivate ihre verwendung als tryptase-inhibitoren
DE3225188A1 (de) Neue phenylessigsaeurederivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
EP1220844B1 (de) Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren
DE3523466A1 (de) Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition